FI933684A - Antiviral 2-hydroximetyl-5-(5-fluorcytosin-1-yl)-1,3-oxatiolan och dess resolution - Google Patents

Antiviral 2-hydroximetyl-5-(5-fluorcytosin-1-yl)-1,3-oxatiolan och dess resolution Download PDF

Info

Publication number
FI933684A
FI933684A FI933684A FI933684A FI933684A FI 933684 A FI933684 A FI 933684A FI 933684 A FI933684 A FI 933684A FI 933684 A FI933684 A FI 933684A FI 933684 A FI933684 A FI 933684A
Authority
FI
Finland
Prior art keywords
fluorcytosin
oxatiolan
hydroximethyl
antiviral
resolution
Prior art date
Application number
FI933684A
Other languages
English (en)
Other versions
FI114915B (fi
FI933684A0 (fi
Inventor
Dennis C Liotta
Raymond F Schinazi
Woo-Baeng Choi
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35276919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI933684(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/659,760 external-priority patent/US5210085A/en
Application filed by Univ Emory filed Critical Univ Emory
Publication of FI933684A0 publication Critical patent/FI933684A0/fi
Publication of FI933684A publication Critical patent/FI933684A/fi
Application granted granted Critical
Publication of FI114915B publication Critical patent/FI114915B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
FI933684A 1991-02-22 1993-08-20 Menetelmä terapeuttisesti käyttökelpoisten beta-2-hydroksimetyyli-5-(5-fluorisytosin-1-yyli)-1,3-oksatiolaanin enantiomeerien valmistamiseksi FI114915B (fi)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US07/659,760 US5210085A (en) 1990-02-01 1991-02-22 Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US65976091 1991-02-22
US73608991A 1991-07-26 1991-07-26
US73608991 1991-07-26
US83115392A 1992-02-12 1992-02-12
US83115392 1992-02-12
US9201339 1992-02-20
PCT/US1992/001339 WO1992014743A2 (en) 1991-02-22 1992-02-20 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane

Publications (3)

Publication Number Publication Date
FI933684A0 FI933684A0 (fi) 1993-08-20
FI933684A true FI933684A (fi) 1993-09-06
FI114915B FI114915B (fi) 2005-01-31

Family

ID=35276919

Family Applications (2)

Application Number Title Priority Date Filing Date
FI933684A FI114915B (fi) 1991-02-22 1993-08-20 Menetelmä terapeuttisesti käyttökelpoisten beta-2-hydroksimetyyli-5-(5-fluorisytosin-1-yyli)-1,3-oksatiolaanin enantiomeerien valmistamiseksi
FI20030932A FI20030932A (fi) 1991-02-22 2003-06-24 Menetelmä cis-FTC:n enantiomeerien erottamiseksi

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20030932A FI20030932A (fi) 1991-02-22 2003-06-24 Menetelmä cis-FTC:n enantiomeerien erottamiseksi

Country Status (25)

Country Link
EP (3) EP0575482A1 (fi)
JP (2) JP2901160B2 (fi)
KR (1) KR0172590B1 (fi)
CN (4) CN1037682C (fi)
AT (2) ATE270291T1 (fi)
AU (2) AU679649B2 (fi)
BG (1) BG62053B1 (fi)
BR (1) BR9205661A (fi)
CA (2) CA2513440C (fi)
CZ (1) CZ295074B6 (fi)
DE (2) DE69233379T2 (fi)
DK (2) DK0984013T3 (fi)
ES (2) ES2345102T3 (fi)
FI (2) FI114915B (fi)
HK (1) HK1026419A1 (fi)
HU (2) HU227823B1 (fi)
IE (1) IE920545A1 (fi)
IL (1) IL100965A (fi)
MX (1) MX9200747A (fi)
MY (1) MY114350A (fi)
NO (3) NO312399B1 (fi)
NZ (2) NZ241625A (fi)
PT (1) PT100151B (fi)
RO (2) RO122814B1 (fi)
WO (1) WO1992014743A2 (fi)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684164A (en) * 1988-04-11 1997-11-04 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
EP0674634B1 (en) * 1989-02-08 2003-04-16 Biochem Pharma Inc Process for preparing substituted 1,3-oxathiolanes with antiviral properties
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6346627B1 (en) 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
ATE219366T1 (de) * 1991-03-06 2002-07-15 Univ Emory Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
ES2138624T3 (es) * 1992-05-13 2000-01-16 Wellcome Found Combinaciones terapeuticas.
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
TW374087B (en) * 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
EP0717628A4 (en) * 1993-09-10 1999-05-26 Univ Emory NUCLEOSIDES ACTIVATED AGAINST HEPATITIS B VIRUS
GB9320316D0 (en) * 1993-10-01 1993-11-17 Smithkline Beecham Plc Pharmaceuticals
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
ATE346651T1 (de) 1995-06-07 2006-12-15 Univ Emory Nucleoside mit anti-hepatitis b virus wirksamkeit
US6544961B1 (en) 1996-06-25 2003-04-08 Smithkline Beecham Corporation Combinations comprising VX478, zidovudine, FTC and/or 3TC for use in the treatments of HIV
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
ATE267198T1 (de) 1997-03-19 2004-06-15 Univ Emory Synthese und anti-hiv und anti-hepatitis virus aktivität von 1,3-oxaselenolan nucleosiden
IT1290447B1 (it) 1997-03-28 1998-12-03 Zambon Spa Derivati 1,3-ossatiolanici ad attivita' antivirale
EP0986375A2 (en) 1997-04-07 2000-03-22 Triangle Pharmaceuticals Inc. Use of mkc-442 in combination with other antiviral agents
AU2241799A (en) * 1998-01-26 1999-08-09 Pharm-Eco Laboratories, Inc. Enzyme activated supports for enantiomeric separations
AU2787199A (en) 1998-02-25 1999-09-15 Emory University 2'-fluoronucleosides
ES2537540T3 (es) * 1998-08-12 2015-06-09 Gilead Sciences, Inc. Método de fabricación de nucleósidos de 1,3-dioxolano y 1,3-oxatiolano
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
CA2355712C (en) 1998-12-23 2009-03-17 Shire Biochem Inc. Antiviral nucleoside analogues
KR100339786B1 (ko) * 1999-04-02 2002-06-07 안용현 라세미 혼합물 상태로 존재하는 뉴클레오시드로부터 거울상 이성질체의 분리 방법
EP1600452A3 (en) 1999-11-12 2008-09-10 Pharmasset, Inc. Synthesis of 2'-deoxy-L-nucleosides
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
CA2308559C (en) 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
ATE491459T1 (de) 2000-10-18 2011-01-15 Pharmasset Inc Modifizierte nukleoside zur behandlung von virusinfektionen und abnormaler zellulärer proliferation
US6828119B2 (en) * 2001-01-04 2004-12-07 Bristol Myers Squibb Company Enzymatic deprotection of amines and hydroxides
DE10104231A1 (de) 2001-01-31 2002-08-08 Consortium Elektrochem Ind Verfahren zur enzymatischen Herstellung von enantiomerenreinen 1,3-Dioxolan-4-on-Derivaten
AU2002335489B2 (en) * 2001-03-01 2008-06-05 Abbott Laboratories Polymorphic and other crystalline forms of cis-FTC
AU2008202336B2 (en) * 2001-03-01 2011-11-10 Abbvie Inc. Polymorphic and other crystalline forms of cis-FTC
EP1495040A4 (en) 2002-04-12 2006-01-25 Achillion Pharmaceuticals Inc PROCESS FOR THE SYNTHESIS OF BETA-L-FLUORO-2 ', 3'-DIDEOXY-DIDEHYDROCYTIDINE (BETA-L-FD4C)
US7955835B2 (en) * 2002-11-18 2011-06-07 Shire Canada Inc. Stereoselective process for the production of dioxolane nucleoside analogues
US20040224916A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
ITMI20030578A1 (it) * 2003-03-24 2004-09-25 Clariant Lsm Italia Spa Processo ed intermedi per la preparazione di emtricitabina
MX2007011274A (es) * 2005-03-14 2008-03-13 Shire Canada Inc Procesos y metodos para la preparacion de cis-2-hidroximetil-4-(ci tosin-1-il)-1,3-oxatiolano opticamente activas o sales aceptables farmaceuticamente del mismo.
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
JP2010520200A (ja) 2007-02-28 2010-06-10 クオナトウス ファーマシューティカルズ，インコーポレイテッド 特定のマトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤を使用する肝疾患を治療する方法
EP2159224B1 (en) 2007-06-18 2012-08-01 Sunshine Lake Pharma Co., Ltd Bromo-phenyl substituted thiazolyl dihydropyrimidines
WO2009084033A2 (en) 2007-12-07 2009-07-09 Matrix Laboratories Limited Process for producing 5-fluoro-1-(2r,5s)-[2-(hydroxymethyl)-1,3-oxathiolan-5-yi]cytosine
WO2009107692A1 (ja) * 2008-02-29 2009-09-03 株式会社カネカ ２’－水酸基が保護されたリボヌクレオシド誘導体およびその製造方法
EP2376514A2 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
PA8855801A1 (es) 2008-12-23 2010-07-27 Sintesis de nucleosidos de purina
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
EP2377862A1 (en) 2010-03-29 2011-10-19 Esteve Química, S.A. Process for obtaining emtricitabine
US8859756B2 (en) 2010-03-31 2014-10-14 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
CN103491948B (zh) 2010-11-19 2016-11-02 吉利德科学公司 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物
AU2013257951A1 (en) 2012-05-11 2015-01-22 Akron Molecules Ag Use of compounds for the treatment of pain
WO2014068265A1 (en) 2012-10-29 2014-05-08 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
CN102911167B (zh) * 2012-11-09 2014-06-25 合肥工业大学 一种高光学纯度的核苷类中间体的制备方法
CN104059057A (zh) * 2014-01-03 2014-09-24 石家庄龙泽制药有限公司 拉米夫定杂质3-tu的制备方法
CN108285895B (zh) * 2018-01-26 2020-06-23 中国科学院南海海洋研究所 一种酯酶EstC11及其编码基因和应用
KR102069443B1 (ko) 2018-08-31 2020-01-22 (주)대한뷰티산업진흥원 울금, 비트 및 무 추출물을 포함하는 바이오셀룰로오스 및 이의 제조방법
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN114190092B (zh) * 2020-07-14 2023-07-18 四川大学 3-去氧-2-酮糖酸含氮衍生物及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914028A (en) * 1988-02-10 1990-04-03 Eli Lilly And Company Method of preparing beta-2',2'-difluoronucleosides
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
AU8864191A (en) * 1990-11-13 1992-06-11 Biochem Pharma Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
ATE219366T1 (de) 1991-03-06 2002-07-15 Univ Emory Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b

Also Published As

Publication number Publication date
AU1561792A (en) 1992-09-15
CA2104399A1 (en) 1992-08-23
AU665187B2 (en) 1995-12-21
JP3292830B2 (ja) 2002-06-17
IE920545A1 (en) 1992-08-26
HK1026419A1 (en) 2000-12-15
CN1084745C (zh) 2002-05-15
CN1109108C (zh) 2003-05-21
EP0984013B1 (en) 2004-06-30
MY114350A (en) 2002-10-31
CN1203232A (zh) 1998-12-30
ES2345102T3 (es) 2010-09-15
CA2104399C (en) 2005-10-18
RO119365B1 (ro) 2004-08-30
EP0984013A3 (en) 2000-08-02
AU3794395A (en) 1996-03-14
CN100396785C (zh) 2008-06-25
ATE270291T1 (de) 2004-07-15
HU227823B1 (en) 2012-03-28
IL100965A (en) 1999-12-31
FI20030932A (fi) 2003-06-24
NO312399B1 (no) 2002-05-06
KR0172590B1 (ko) 1999-02-01
JP2901160B2 (ja) 1999-06-07
HUT65548A (en) 1994-06-28
DE69233786D1 (de) 2010-07-08
MX9200747A (es) 1992-09-01
CN1065065A (zh) 1992-10-07
ATE469147T1 (de) 2010-06-15
NO2005015I2 (no) 2007-10-01
DK0984013T3 (da) 2004-10-25
NZ250842A (en) 1996-03-26
EP0984013A2 (en) 2000-03-08
IL100965A0 (en) 1992-11-15
HU211344A9 (en) 1995-11-28
BG98062A (bg) 1994-04-29
FI114915B (fi) 2005-01-31
PT100151A (pt) 1993-05-31
JPH06508605A (ja) 1994-09-29
RO122814B1 (ro) 2010-02-26
CA2513440A1 (en) 1992-09-03
EP1439177A1 (en) 2004-07-21
FI933684A0 (fi) 1993-08-20
EP0575482A1 (en) 1993-12-29
NO932980L (no) 1993-08-20
WO1992014743A3 (en) 1992-10-29
NO2008010I1 (no) 2008-07-07
NO932980D0 (no) 1993-08-20
NZ241625A (en) 1996-03-26
CA2513440C (en) 2010-11-30
CN1127301A (zh) 1996-07-24
NO2005015I1 (no) 2005-07-11
CZ295074B6 (cs) 2005-05-18
CN1418966A (zh) 2003-05-21
BG62053B1 (bg) 1999-01-29
CZ49792A3 (en) 1993-03-17
EP1439177B1 (en) 2010-05-26
JPH10147586A (ja) 1998-06-02
DK1439177T3 (da) 2010-08-02
DE69233379D1 (de) 2004-08-05
AU8077398A (en) 1998-10-15
PT100151B (pt) 1999-09-30
BR9205661A (pt) 1994-05-24
ES2224547T3 (es) 2005-03-01
DE69233379T2 (de) 2005-07-14
WO1992014743A2 (en) 1992-09-03
HU9302377D0 (en) 1993-11-29
AU679649B2 (en) 1997-07-03
CN1037682C (zh) 1998-03-11

Similar Documents

Publication Publication Date Title
FI933684A0 (fi) Antiviral 2-hydroximetyl-5-(5-fluorcytosin-1-yl)-1,3-oxatiolan och dess resolution
ATE138065T1 (de) Substituierte 1,3-oxathiolane mit antiviraler wirkung
DE69232845D1 (de) 1,3-Oxathiolannukleosid-analoge Verbindungen
TW366346B (en) 1,3-oxathiolane nucleoside analogue
IL89921A (en) 1,3-dioxolane derivatives and pharmaceutical compositions containing the same
DK0574487T3 (da) Anvendelse af 5-fluor-2'-deoxy-thiacytidin til behandling af hepatitis B
FI933248A0 (fi) Optiskt aktiva 5h-pyrrolo(3,4-b)pyrazinderat, dess framstaellning och farmaceutiska kompositioner innehaollande detta
IL101836A0 (en) Pharmaceutical compositions containing 1,3-oxathiolane nucleoside derivatives
DZ1576A1 (fr) Compostions therapeutiques à base de dérives de 1,2-dithiole-3-thione.
FI933477A0 (fi) Monohydrat av ett dinatriumsalt av 4-klorfenyltiometylenbisfosfonsyra,dess framstaellning och farmaceutiska kompositioner innehaollande detta
BA96098A (bs) 1,3-Oksatiolanski nukleozidni analozi
FI924939A (fi) Nya kinoloner, foerfarande foer framstaellning daerav och farmaceutiska kompositioner innehaollande dessa
LV5730B4 (lv) 2- un 5-aizvietoti 1,3-oksatiolani ar antiviralam ipasibam

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 114915

Country of ref document: FI

SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20050018

MA Patent expired